New study explores the genetic connection between COVID-19 and gastric cancer

Medical News: Bioinformatics and Systems Biology Reveal Shared Pathways
A groundbreaking study has recently explored a critical and under-examined link between COVID-19 and gastric cancer (GC). While the coronavirus has predominantly affected respiratory systems, this study presents compelling evidence that COVID-19 might play a role in worsening or even promoting gastric cancer. Researchers from West China Hospital, Sichuan University have turned to bioinformatics and systems biology to examine this association, discovering shared molecular mechanisms that could help guide future treatments.


Study explores the genetic connection between COVID-19 and gastric cancer

The idea behind the study is simple: since cancer patients often have compromised immune systems, they are at higher risk when exposed to infections like COVID-19. However, researchers went beyond this basic assumption to explore the deep molecular similarities between the two diseases. This Medical News report dives into the findings, exploring the shared genes, immune responses, and potential drug therapies that might target both COVID-19 and gastric cancer (GC.
 
Background and Methodology
COVID-19, caused by the virus SARS-CoV-2, has shaken the world, and researchers continue to find new ways it interacts with various health conditions. Gastric cancer, one of the leading causes of cancer-related deaths globally, has a strong association with weakened immune systems, which are also vulnerable to the virus. This combination makes it essential to understand how both conditions might be biologically linked.
 
To uncover the shared biological pathways, the team employed cutting-edge bioinformatics tools. They analyzed gene expression profiles from both COVID-19 and gastric cancer patients using datasets from the Gene Expression Omnibus (GEO) database. The analysis revealed 209 differentially expressed genes (DEGs) common to both COVID-19 and gastric cancer. The study took a deeper dive into how these genes impact immune responses, identifying the key players responsible for the shared disease mechanisms.
 
The study also analyzed how these genes interacted with each other using protein-protein interaction (PPI) networks and identified several "hub genes" central to both diseases. Furthermore, potential drugs that target these shared genes were predicted, opening doors to novel therapeutic strategies.
 
Key Study Findings
The research team's findings are impressive and far-reaching. By identifying 209 shared DEGs between COVID-19 and gastric cancer, the study offers a novel insight into the molecular ties between these two conditions. Many of these genes are crucial to immune system pathways, suggesting that the body’s response to SARS-CoV-2 might also influence the development or progression of gastric cancer.
 
Hub Genes: The Central Players
A core finding of the study is the identification of 10 hub genes that are key players in both COVID-19 and gastric cancer. These genes - CDK1, KIF20A, TPX2, UBE2C, HJURP, CENPA, PLK1, MKI67, IFI6, and IFIT2 - are essential for regulating critical biological processes such as cell division, immune responses, and tumor progression.
 
For instance, CDK1 plays a crucial role in cell cycle regulation. Its heightened expression in both diseases indicates that it could be driving the uncontrolled cell division seen in gastric cancer while also being involved in the immune cell dysfunction observed in severe COVID-19 cases. Similarly, genes like KIF20A and TPX2, known for their roles in cell division and spindle formation, show how the same biological pathways might be manipulated in both COVID-19 and gastric cancer (GC).
 
Immune System and Disease Pathways
Another critical aspect of the research is the focus on immune-related pathways. The shared DEGs were found to be significantly enriched in several immune-related pathways, such as neutrophil activation and cytokine activity. This highlights the importance of immune system dysregulation in both diseases. COVID-19 is known for triggering a hyperactive immune response, often leading to cytokine storms, which can exacerbate gastric cancer in already immunocompromised patients.
 
Moreover, neutrophils, a type of white blood cell essential for fighting infections, are affected in both conditions. Dysfunctional neutrophil activity is a hallmark of severe COVID-19 cases and also plays a role in tumor progression. This shared characteristic opens new possibilities for targeting immune pathways to treat both diseases.
 
Potential Drug Therapies
One of the most exciting aspects of this research is the identification of 10 potential therapeutic agents that could target the shared molecular mechanisms of COVID-19 and gastric cancer. These drugs include commonly known medications like ciclopirox, resveratrol, methotrexate, and dasatinib, each of which has shown promise in treating either gastric cancer or COVID-19 in past studies.
 
For example, ciclopirox, traditionally used as an antifungal, has shown potential in cancer treatment by inhibiting pathways that promote tumor growth.
 
Interestingly, ciclopirox has also been identified as a possible treatment for COVID-19 due to its ability to disrupt viral replication.
 
Resveratrol, a compound found in grapes and berries, is another potential therapy. Known for its antioxidant and anti-inflammatory properties, resveratrol might help mitigate the effects of both gastric cancer and COVID-19 by reducing inflammation and promoting apoptosis (programmed cell death) in cancer cells.
 
The study also identifies other potential treatments, such as etoposide, trifluridine, calcitriol, and deferoxamine, further enriching the possibilities for cross-disease therapeutic strategies.
 
Conclusion: What the Study Means for the Future
This research has the potential to reshape how we approach the treatment of both COVID-19 and gastric cancer. By uncovering the shared molecular mechanisms, researchers have provided valuable insights that could guide future therapeutic strategies. The discovery of hub genes and immune-related pathways common to both diseases underscores the importance of targeting these areas for treatment.
 
The therapeutic agents identified in this study offer hope for future treatments that might be effective for patients battling both COVID-19 and gastric cancer. While the study is still in its early stages, these findings could pave the way for clinical trials aimed at testing these therapies in real-world settings.
 
As COVID-19 continues to evolve and affect various aspects of health, including cancer development and progression, this research is a significant step toward developing more effective treatments. The insights provided by this study could help medical professionals better manage the challenges posed by both diseases.
 
The study findings were published in the peer-reviewed journal: Frontiers in Medicine.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1428973/full
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/smarcd3-a-key-player-in-gastric-cancer-progression
 
https://www.thailandmedical.news/news/the-phytochemical-erianin-found-in-dendrobium-orchids-shows-promise-in-fighting-gastric-cancer